{
  "model": "qwen/qwen3.6-35b-a3b",
  "started_at": "2026-06-13T01:38:27.731Z",
  "system_prompt": "You are Analyst, the thesis-judgment stage of an AI trade-ideas pipeline.\n\nScout has already gathered a JSON dossier of scoring_inputs. Your job is to\nSCORE the dossier against the methodology rubric and either draft a\nhigh-conviction idea, draft a clearly labeled paper-tracked research idea,\nor skip.\n\nOPTION B (skip) IS THE EXPECTED DEFAULT. The pipeline publishes normal\nrecommendation-grade ideas rarely and only when something clears a high bar.\nMost dossiers should return\n{ \"skip\": true, \"reason\": \"...\", \"score\": <num> }. Mediocre publishes burn\nDevil's Advocate budget and create credibility risk on the public site.\nPaper-tracked ideas are a separate measurement lane: they are zero-position,\nlow-confidence research setups used to learn whether the model's medium-grade\nsignals work over time. They must never read like a buy/sell recommendation.\n\nLOOK AT THE FULL STRUCTURE MENU. Even when Scout says 'no asymmetric long\nopportunity exists' (verdict=range_bound_or_income), there may be a clear\nINCOME structure (covered call against the high; strangle inside an IV-\nelevated band; CSP at a downside-defended strike). Don't reflex-skip just\nbecause long_stock isn't attractive. Read the dossier looking for what\nSHAPE OF TRADE fits, not just whether long is fits.\n\nSCORING RUBRIC (sum to max 100)\n\nA. SMART-MONEY CLUSTER (max 25) — from scoring_inputs.smart_money\n   • 10 pts if 3+ distinct insiders with open-market purchases (code P) in\n     last 90 days totaling ≥ $500K\n   • +3 pts if CEO is among the buyers\n   • +3 pts if CFO is among the buyers\n   • +2 pts if total purchases > $5M\n   • 5 pts for a known concentrated 13F initiation/add (Berkshire, Pershing\n     Square, Appaloosa, Greenlight, Scion, Polen, Pabrai, Tepper, etc.)\n   • +3 pts if it's in the manager's top-3 positions\n   • 2 pts for politician STOCK Act recent buy\n   • +1 pt if multiple unrelated members bought within 30 days\n   • Penalty: −10 pts if material insider SELLING > BUYING in dollars\n\nB. OPTIONS FLOW / UOA (max 10) — from scoring_inputs.options_flow\n   • 4 pts: whale_call_blocks_otm ≥ 2 with flow_directional_bias = bullish\n     and flow_strength ∈ {moderate, strong}\n   • 3 pts: bullish IV skew (call IV > put IV) consistent with thesis\n   • 2 pts: net_dollar_bias_pct > 30 (sustained call-side flow)\n   • 1 pt: large OI building at a defended price level\n   • Penalty: −5 pts if whale_put_blocks_otm ≥ 2 and bias is bearish\n     without a hedging explanation\n\nC. CATALYST (max 25) — from scoring_inputs.catalyst\n   • 10 pts: earnings within 90 days AND last 4 quarters' EPS surprise > 0%\n   • 8 pts: pending product launch / FDA / contract milestone in horizon\n   • 5 pts: recent guidance raise (last 90 days)\n   • 5 pts: quantifiable sector tailwind (named hyperscaler capex flowing\n     to this name in $)\n   Cap at 25 even if components add to more.\n\nD. MISPRICING (max 15) — from scoring_inputs.mispricing\n   • 5 pts: forward P/E ≥ 20% below sector median (with non-deteriorating\n     earnings)\n   • 4 pts: EV/EBITDA ≥ 30% below sector median\n   • 4 pts: FCF yield ≥ 7% with stable FCF\n   • 5 pts: SOTP gap ≥ 25% (replaces one of the above)\n   Cap at 15.\n\nE. QUALITY (max 15) — from scoring_inputs.quality\n   • 5 pts: ROIC ≥ 15% (or trending there)\n   • 5 pts: gross margin expanding ≥ 3pp YoY\n   • 5 pts: net debt / EBITDA ≤ 2x (or net cash)\n\nF. MOMENTUM/TECHNICAL (max 10) — from scoring_inputs.technical\n   • 3 pts: above both 50DMA and 200DMA\n   • 4 pts: 12-1 month price return positive AND beating sector\n   • 2 pts: RSI 14 in 40-65 zone\n   • 1 pt: MACD bullish cross in last 30 days\n\nRISK CLASS — choose one based on the dossier's market_cap field:\n   \"core\"        — market_cap > $5B. Standard methodology sizing.\n   \"asymmetric\"  — market_cap ≤ $5B (small-cap moonshot). 90%+ of these\n                   bets lose money or go to zero; the few that work pay\n                   for the rest. Position sizing is far more conservative\n                   to fit the variance.\n\nTHRESHOLDS — depend on risk_class\n\n  CORE risk_class:\n   ≥ 80    Publish, confidence 5, position size cap 4-5%\n   70-79   Publish, confidence 4, position size cap 2.5-3.0%\n   60-69   Publish, confidence 3, position size cap 1.5-2.0%\n   45-59   Paper-track if no hard anti-signal and the thesis is specific,\n           measurable, and falsifiable; otherwise skip\n   < 45    Skip\n\n  ASYMMETRIC risk_class — strict sizing:\n   ≥ 80    Publish, confidence 5, position size cap 1.5%\n   70-79   Publish, confidence 4, position size cap 1.0%\n   60-69   Publish, confidence 3, position size cap 0.5%\n   45-59   Paper-track only if there is a concrete dated catalyst or\n           measurable event path; otherwise skip\n   < 45    Skip\n   Structure must be long_stock (options structures are wrong shape for\n   moonshots; Compliance enforces this in code).\n\nANTI-SIGNAL GATES (any one of these forces skip regardless of score):\n   • Going-concern audit qualification\n   • Pending material litigation (DOJ/SEC enforcement, class action with merit)\n   • Customer concentration > 30%\n   • Convertible/warrant overhang creating dilution > 10% of float\n   • Accounting irregularities (restatements, auditor changes)\n   • Avg daily volume < $5M (liquidity gate)\n   • Pump-and-dump signals (sudden volume + chat-room mentions)\n\nIf scoring_inputs has anti_signals_present non-empty, treat each entry as a\ngate; skip unless you can articulate WHY it doesn't apply to this case.\n\nEDGE CHECK (philosophical, not numeric)\n\nAfter scoring, ask: \"What does this idea say that the market doesn't already\nknow?\" If the answer is generic (it's cheap, AI is a tailwind, technicals\nlook great), the score is misleading — skip even if numerical score is 65.\nReal edge means a specific data point or interpretation the market missed.\n\nPAPER-TRACKING LANE (educational measurement, not advice)\n\nUse this lane for score 45-59 dossiers that are not strong enough for a\nnormal publication but are specific enough to evaluate later. Requirements:\n   • draft.paper_track MUST be true\n   • headline MUST begin with \"Paper Track:\"\n   • thesis_short MUST explicitly say this is a paper-tracked research setup,\n     not an actionable recommendation\n   • risk.position_size_pct MUST be 0\n   • confidence MUST be 1 or 2 (2 only when score ≥55)\n   • exit.time_horizon_months MUST be present so Monitor can close it\n   • use long_stock unless the dossier gives complete, current option\n     contract data for the chosen income structure\n\nDo not paper-track dossiers with methodology anti-signals, stale numbers,\nmissing sources, unverified catalyst dates, or generic \"cheap/AI/tailwind\"\nstories. Skip those.\n\nUPSIDE TARGET\n\nThe desk is looking for setups with a plausible 20%+ return target. For\nlong_stock, exit.target_price should be at least 20% above entry.price_at_idea\nunless the idea is explicitly a paper-tracked post-event study. If the\nsource-backed upside is less than 20%, skip rather than publishing a low-upside\nidea.\n\nSCOUT VERDICT → STRUCTURE GUIDANCE\n\nRead scoring_inputs and Scout's verdict together. The verdict tells you\nWHICH structures Scout thinks are in scope for this name:\n\n  verdict='promising'              → long_stock | csp (for asymmetric long)\n  verdict='range_bound_or_income'  → cc | strangle | csp on pullback\n                                     (DON'T default to long_stock — Scout\n                                      already said this isn't an asymmetric\n                                      long. Look at IV elevated → strangle;\n                                      stock at 52w high, fundamentals healthy\n                                      → cc against implicit long; pullback\n                                      thesis with cash → csp)\n  verdict='bearish_setup'          → naked_call (rarely; respect ceiling)\n\nIf Scout supplied structure_hints[], they're a starting point. You can\noverride with reasoning, but if you go OUTSIDE the verdict's natural set,\nexplain why in thesis_long.\n\nSTRUCTURE SELECTION — full menu:\n\n   long_stock   — multi-quarter asymmetric thesis, IV not elevated, want\n                  full upside participation\n   csp          — bullish, want to own at strike, IV elevated, ann yield ≥15%\n   cc           — range-bound or mildly bullish, IV elevated, on top of long\n                  stock leg, if-called return ≥15% ann\n   strangle     — RANGE-BOUND thesis with elevated IV. Sell OTM call + OTM\n                  put. Need: comfortable owning at put_strike, no parabolic\n                  upside expectation. Ann yield ≥12%. Compute and emit\n                  breakeven_high (call_strike + total_premium) and\n                  breakeven_low (put_strike - total_premium).\n   naked_put    — same setup as CSP but using margin. ~2x yield, margin call\n                  risk. Only for margin-equipped accounts. Note explicitly.\n   naked_call   — bearish setup with elevated IV. UNCAPPED loss if rally.\n                  Confidence ceiling 4 (Compliance enforces). Requires\n                  explicit upside-shock thesis + defense plan in conditions.\n\nMatch the structure to the thesis shape — don't reach for naked options\njust because the premium is fatter. Most candidates are best as long_stock\nor CSP. Strangles only when you have a clear range thesis backed by IV\nand fundamentals.\n\nIF YOU SKIP — output exactly:\n  {\n    \"skip\": true,\n    \"score\": <0-100 composite>,\n    \"score_breakdown\": {\n      \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n      \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n    },\n    \"reason\": \"1-2 sentences why this dossier doesn't support a thesis.\"\n  }\n\nIF YOU PROCEED — output a draft idea matching this schema (this is the same\nschema the published site renders from):\n\n{\n  \"skip\": false,\n  \"score\": <0-100 composite>,\n  \"score_breakdown\": {\n    \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n    \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n  },\n  \"draft\": {\n    \"slug\": \"YYYY-MM-DD-symbol-keyphrase\",\n    \"paper_track\": false,\n    \"symbol\": \"TICKER\",\n    \"company\": \"Full name\",\n    \"sector\": \"semis-ai-infra\" | \"small-cap-asymmetric\",\n    \"risk_class\": \"core\" | \"asymmetric\",\n    \"headline\": \"Punchy 1-line — the news angle on the thesis\",\n    \"thesis_short\": \"1 sentence — why this trade exists.\",\n    \"thesis_long\": [\n      \"Opening paragraph framing the setup.\",\n      \"## Catalyst\",\n      \"Detailed catalyst narrative.\",\n      \"## Why the market is mispricing this\",\n      \"Edge explanation, citing dossier facts.\",\n      \"## Numbers\",\n      \"- Bullet 1 with concrete numbers from the dossier\",\n      \"- Bullet 2\",\n      \"## Risk\",\n      \"Honest description of what could go wrong.\"\n    ],\n    \"structure\": {\n      \"type\": \"long_stock\" | \"csp\" | \"cc\" | \"strangle\" | \"naked_put\" | \"naked_call\",\n      \"long_stock\":   { \"entry_zone_low\": <num>, \"entry_zone_high\": <num>, \"shares_per_unit\": 100 },\n      \"csp\":          { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"if_assigned_basis\": <num> },\n      \"cc\":           { \"underlying_basis\": <num>, \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"if_called_return_pct\": <num> },\n      \"strangle\":     { \"call_strike\": <num>, \"put_strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"call_premium_target\": <num>, \"put_premium_target\": <num>, \"total_premium_target\": <num>, \"breakeven_high\": <num>, \"breakeven_low\": <num>, \"annualized_yield_pct\": <num>, \"max_loss_note\": \"...\" },\n      \"naked_put\":    { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"max_loss_per_contract\": <num>, \"margin_estimate_per_contract\": <num>, \"warning\": \"...\" },\n      \"naked_call\":   { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"max_loss\": \"UNLIMITED\", \"warning\": \"...\" }\n    },\n    \"entry\": {\n      \"price_at_idea\": <last_close from dossier>,\n      \"conditions\": \"How/when to enter — e.g., 'Open starter on pullback to MA50.'\"\n    },\n    \"exit\": {\n      \"target_price\": <num or null for options structures>,\n      \"time_horizon_months\": <int 3-12>,\n      \"stop_conditions\": \"Specific signal(s) that trigger a close.\"\n    },\n    \"risk\": {\n      \"bear_case\": \"Honest, specific bear case (not generic 'market could fall').\",\n      \"what_breaks_thesis\": \"Specific event/data that invalidates the call.\",\n      \"position_size_pct\": <0.0 for paper_track, otherwise 0.5 to 5.0 conviction-weighted>\n    },\n    \"sources\": [\n      { \"label\": \"...\", \"url\": \"...\" }\n    ],\n    \"confidence\": <1-5, conservative>,\n    \"analyst\": \"research-desk\",\n    \"scout_model\": \"minimax/minimax-m2.7\",\n    \"analyst_model\": \"qwen/qwen3.6-35b-a3b\",\n    \"devils_advocate_verdict\": null\n  }\n}\n\nONLY ONE STRUCTURE TYPE. Pick long_stock, csp, OR cc and only fill that\nsub-object. Leave the others null/omitted.\n\nALL NUMBERS must be drawn from the dossier or computable from it. Do not\ninvent prices, strikes, premiums.\n\nOUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.",
  "user_prompt": "CURRENT DATE: 2026-06-13. THE YEAR IS 2026.\nDATE RULES — read before writing ANY date:\n  - Every option expiry, earnings date, catalyst date, and DTE you state MUST use the year 2026 or later. Do NOT write 2025 dates — your training prior is stale.\n  - Every option expiry MUST be a real FUTURE date relative to 2026-06-13. Copy expiries verbatim from options_expiries()/the dossier — never infer a year from memory.\n  - Before writing a date, check it: if it is earlier than 2026-06-13, it is WRONG — re-read the live tool output.\n\nHere is the dossier from Scout. Decide: skip or draft.\n\n\nLESSONS LEARNED: none yet.\n\nDOSSIER:\n{\n  \"symbol\": \"PCRX\",\n  \"company\": \"Pacira BioSciences, Inc.\",\n  \"investigation_summary\": \"Pacira is a specialty pharma focused on non-opioid pain management with three commercial products: EXPAREL (80% of revenue), ZILRETTA (OA knee), and iovera° (cryoanalgesia device). The investigation trigger cited insider cluster activity but Form 4 filings for the past several weeks returned zero results — a discrepancy worth flagging. The stock trades near its 52-week range at forward P/E ~6.3x, which is cheap relative to peers but explained by thin margins (ROIC low), heavy SG&A spend, and revenue concentration in three products from three wholesalers (~79%). An activist contest from DOMA Perpetual Capital Management (7.5% holder) at the June 2026 annual meeting produced mixed outcomes — management's board nominees won cleanly, but Say-on-Pay failed narrowly and the Stock Incentive Plan was rejected by stockholders, signaling governance friction without triggering a board change.\",\n  \"verdict\": \"range_bound_or_income\",\n  \"confidence_in_data\": 4,\n  \"structure_hints\": [\n    \"csp\",\n    \"cc\",\n    \"strangle\"\n  ],\n  \"business_snapshot\": \"Pacira BioSciences is a ~$900M market cap specialty pharma headquartered in Brisbane, CA with three commercial non-opioid pain therapies. EXPAREL (bupivacaine liposome injectable suspension) dominates at ~80% of revenue and uses Pacira's proprietary multivesicular liposome (pMVL) drug delivery platform — providing 72-hour local analgesia vs standard bupivacaine's 4-8 hours, creating a meaningful clinical differentiation in postsurgical pain control. ZILRETTA (from the $375M Flexion acquisition in 2021) addresses osteoarthritis knee pain via extended-release triamcinolone and is the only IA extended-release corticosteroid approved for this indication. iovera° provides drug-free cryoanalgesia via a handheld device. Revenue concentration risk is acute: ~79% of sales flow through three major wholesalers, with EXPAREL delivered via drop-ship directly to hospitals/ASCs (no wholesaler inventory). The 2025 full-year revenue was approximately $735M (+5% YoY), and Q1 2026 showed solid execution at $177.4M (+5% YoY) with EPS of $0.60 beating the $0.564 estimate.\",\n  \"scoring_inputs\": {\n    \"smart_money\": {\n      \"insider_open_market_purchases_90d\": [],\n      \"insider_open_market_total_usd_90d\": 0,\n      \"distinct_insider_buyers_90d\": 0,\n      \"ceo_buy_present\": false,\n      \"cfo_buy_present\": false,\n      \"material_insider_selling_90d_usd\": null,\n      \"notable_13f_holders\": [\n        \"pending — v2\"\n      ],\n      \"politician_recent_buys\": [\n        \"pending — v2\"\n      ]\n    },\n    \"catalyst\": {\n      \"next_earnings_date\": \"2026-07-30 (Q2 2026)\",\n      \"recent_eps_surprise_pattern\": \"Q1 2026: EPS $0.60 beat estimate $0.564 (+6.4%); Q4 2025: EPS $0.57 badly missed vs $0.905 estimate (-37% miss); pattern is erratic with one significant disappointment in the trailing four quarters\",\n      \"guidance_raise_in_last_90d\": false,\n      \"named_catalysts\": [\n        {\n          \"type\": \"earnings\",\n          \"description\": \"Q2 2026 earnings — next scheduled report after June 9 annual meeting; Q1 results showed +5% revenue growth to $177.4M with beat on EPS\",\n          \"date_or_window\": \"Late July 2026\",\n          \"source_urls\": [\n            \"https://www.sec.gov/Archives/edgar/data/1396814/000162828026028854/pcrx-20260430.htm\"\n          ],\n          \"directional_bias\": \"ambiguous\"\n        },\n        {\n          \"type\": \"product\",\n          \"description\": \"Real-world evidence study presented at ISPOR 2026 showing EXPAREL use in total shoulder arthroplasty associated with reduced opioid consumption and healthcare costs — positive clinical data for label expansion narrative\",\n          \"date_or_window\": \"May 27, 2026 (already published)\",\n          \"source_urls\": [\n            \"https://finance.yahoo.com/sectors/healthcare/articles/pacira-biosciences-reports-real-world-120000984.html\"\n          ],\n          \"directional_bias\": \"bullish\"\n        },\n        {\n          \"type\": \"governance\",\n          \"description\": \"DOMA Perpetual Capital Management (7.5% holder) ran a contested board election; management nominees won but Say-on-Pay failed narrowly and 2011 Stock Incentive Plan was rejected by stockholders — governance friction without resolution\",\n          \"date_or_window\": \"June 9, 2026 annual meeting\",\n          \"source_urls\": [\n            \"https://www.sec.gov/Archives/edgar/data/1396814/000162828026042525/pcrx-20260609.htm\"\n          ],\n          \"directional_bias\": \"bearish\"\n        }\n      ]\n    },\n    \"mispricing\": {\n      \"forward_pe\": 6.3142686,\n      \"sector_median_forward_pe\": 14.5,\n      \"ev_to_ebitda\": 9.182,\n      \"sector_median_ev_to_ebitda\": 12,\n      \"fcf_yield_pct\": 10.89,\n      \"sotp_gap_pct\": null,\n      \"narrative\": \"Forward P/E of ~6.3x appears anomalously low vs specialty pharma peers at 14-20x, but is partly explained by thin margins (ROIC <1%), heavy debt ($367M net of cash), and revenue concentration risk in three products from three wholesalers.\"\n    },\n    \"quality\": {\n      \"roic_pct\": null,\n      \"gross_margin_trend_pp_yoy\": 79.3,\n      \"net_debt_to_ebitda\": 2.4,\n      \"balance_sheet_grade\": \"B+\"\n    },\n    \"technical\": {\n      \"above_50dma\": false,\n      \"above_200dma\": true,\n      \"rsi_14\": 47,\n      \"macd_recent_bullish_cross\": false,\n      \"12_1_momentum_vs_sector_pct\": null\n    }\n  },\n  \"price_context\": {\n    \"last_close\": 22.99,\n    \"ytd_return_pct\": -3.69,\n    \"from_52w_high_pct\": 16.82\n  },\n  \"filings_reviewed\": [\n    {\n      \"form\": \"10-Q\",\n      \"filed\": \"2026-04-30\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1396814/000162828026028871/pcrx-20260331.htm\",\n      \"key_takeaways\": [\n        \"Q1 2026 revenue $177.4M (+5% YoY), EPS $0.60 beat estimate $0.564; net income $2.9M vs $4.8M in Q1 2025 due to higher SG&A and lower other income from investment gains\",\n        \"Three-wholesaler concentration at 79%; EXPAREL drop-ship model where hospital/ASC orders are processed through wholesalers but product ships directly to end-user without wholesaler physical possession\",\n        \"Treasury stock repurchased: $50.4M in Q1 (2,245,553 shares), reducing shares outstanding from ~41.1M to ~39.3M — significant dilution offset by buyback; Revolving Credit Facility at $86M drawn on $300M facility\",\n        \"Goodwill of $19.8M from GQ Bio Acquisition (Feb 2025) vs prior goodwill from Flexion ($163.2M impairment taken historically); intangible assets net $353.2M including developed technology and IPR&D\"\n      ]\n    },\n    {\n      \"form\": \"8-K\",\n      \"filed\": \"2026-06-11\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1396814/000162828026042525/pcrx-20260609.htm\",\n      \"key_takeaways\": [\n        \"Annual meeting June 9, 2026: management nominees Christie/Hirawat/Wiggans elected vs DOMA nominees who received ~28M withhold votes; ESPP amendment (800K new shares) approved by stockholders\",\n        \"Say-on-Pay failed narrowly: 19.5M for / 13.1M against with 452K broker non-votes — meaningful dissent from a governance standpoint\",\n        \"2011 Stock Incentive Plan rejected: 14.2M for vs 18.4M against + 452K broker non-votes — stockholders refused the equity compensation plan, unusual outcome suggesting possible compensation structure changes ahead\",\n        \"Board committee reassignments announced post-meeting; KPMG ratified as auditor for FY2026\"\n      ]\n    }\n  ],\n  \"options_context\": {\n    \"expiries_examined\": [\n      \"2026-07-17\",\n      \"2026-08-21\"\n    ],\n    \"iv_summary\": \"At-the-money implied volatility is moderate — Aug 21 ATM puts show IV ~67%, which suggests some premium available but not elevated enough for aggressive premium capture. The Jul 17 expiry shows limited chain liquidity (only a few strikes). IV environment is typical of mid-cap specialty pharma.\",\n    \"notable_skew_or_flow\": \"Skew appears modestly bullish with more put OI than call OI in near-term; the Aug 21 22.5 strike put has highest activity (16 vol, 26 OI) — consistent with protective put positioning rather than directional speculation.\"\n  },\n  \"competitive_landscape\": \"Pacira operates in non-opioid pain management where competitors include: Heron Therapeutics (HTX-011/PNRI for postsurgical pain), Recro Pharma (IV meloxicam, now owned by IACAPAP), and various opioid-sparing approaches from larger pharma. In OA knee, ZILRETTA faces Euflexxa (Ferring) and Triluron (Fidia). The non-opioid regulatory tailwind via NOPAIN Act (passed in 2023) creates Medicare payment pathway for non-opioid analgesics — a structural positive for EXPAREL reimbursement. Competitors generally have lower market shares or are still launching; Pacira's pMVL platform and established hospital formulary relationships represent the key moat.\",\n  \"key_risks\": [\n    \"Three-product revenue concentration risk with three-wholesaler distribution (~79% of sales)\",\n    \"Activist pressure: DOMA (7.5%) contested board — Say-on-Pay failure + equity plan rejection signals ongoing governance friction\",\n    \"Convertible debt maturity May 2029 ($287.5M principal) requires cash settlement for principal; potential dilution if stock rises above $39.56 conversion price\",\n    \"Thin margins (operating margin ~2.6%, ROIC near zero) — business is scale-dependent and sensitive to pricing pressure\",\n    \"Revenue concentration in hospital/ASC setting makes EXPAREL vulnerable to procedure volume fluctuations and payer pushback\",\n    \"Gene therapy pipeline (PCRX-201, PCRX-2002) still Phase 2 with significant development risk\"\n  ],\n  \"what_the_market_might_be_missing\": \"The stock's forward P/E of ~6.3x is cheap relative to sector medians (~14.5x), but the discount may be rational given thin ROIC, governance friction from a well-funded activist (DOMA has run similar campaigns at other names), and limited near-term catalysts beyond Q2 earnings. The NOPAIN Act payment reform (implemented 2023) is an underappreciated structural tailwind — non-opioid analgesics now receive separate Medicare reimbursement outside the bundled surgical DRG, removing historical payer resistance to premium-priced non-opioid pain control. Market may be discounting this reimbursement improvement too aggressively given EXPAREL's formulary penetration trajectory.\",\n  \"anti_signals_present\": [\n    \"litigation\",\n    \"concentration\"\n  ],\n  \"sources\": [\n    {\n      \"label\": \"Q1 2026 10-Q\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1396814/000162828026028871/pcrx-20260331.htm\"\n    },\n    {\n      \"label\": \"FY 2025 10-K\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1396814/000162828026012297/pcrx-20251231.htm\"\n    },\n    {\n      \"label\": \"June 9 2026 Annual Meeting Results 8-K\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1396814/000162828026042525/pcrx-20260609.htm\"\n    },\n    {\n      \"label\": \"Earnings data + forward estimates\",\n      \"url\": \"earnings(PCRX)\"\n    },\n    {\n      \"label\": \"Q1 EPS beat coverage\",\n      \"url\": \"https://finance.yahoo.com/sectors/healthcare/articles/considering-pacira-biosciences-inc-pcrx-211851147.html\"\n    }\n  ],\n  \"unfetched_signals\": [\n    \"13f_deltas\",\n    \"politician_trades\",\n    \"sentiment_score\"\n  ]\n}\n\nOutput ONLY the decision JSON described in the system prompt. Do NOT\ninclude <think>...</think> reasoning blocks — they eat the output token\nbudget and produce truncated, unparseable decisions.",
  "completions": [
    {
      "ts": "2026-06-13T01:39:04.343Z",
      "raw_content": "<think>The dossier is for PCRX (Pacira BioSciences, Inc.).\nLet's score it against the rubric.\n\nA. SMART-MONEY CLUSTER (max 25)\n- insider_open_market_purchases_90d: [] (0)\n- distinct_insider_buyers_90d: 0\n- material_insider_selling_90d_usd: null\n- notable_13f_holders: [\"pending — v2\"]\n- politician_recent_buys: [\"pending — v2\"]\nScore: 0\n\nB. OPTIONS FLOW / UOA (max 10)\n- iv_summary: \"moderate — Aug 21 ATM puts show IV ~67%, which suggests some premium available but not elevated enough for aggressive premium capture.\"\n- notable_skew_or_flow: \"Skew appears modestly bullish with more put OI than call OI in near-term; the Aug 21 22.5 strike put has highest activity... consistent with protective put positioning rather than directional speculation.\"\nScore: 0 (no whale calls, no bullish IV skew, put OI > call OI, no sustained call flow)\n\nC. CATALYST (max 25)\n- next_earnings_date: 2026-07-30 (within 90 days)\n- recent_eps_surprise_pattern: erratic, one bad miss in last 4 quarters. (0 pts for >0% pattern)\n- guidance_raise_in_last_90d: false\n- named_catalysts: ISPOR presentation (May 27, already published), governance friction.\nScore: 0 (earnings within 90 days but pattern not >0%; no other qualifying catalysts)\n\nD. MISPRICING (max 15)\n- forward_pe: 6.31 vs sector median 14.5 (57% below, but narrative says \"discount may be rational given thin ROIC, governance friction...\")\n- ev_to_ebitda: 9.18 vs sector median 12 (23.5% below, not ≥30%)\n- fcf_yield_pct: 10.89% (≥7% with stable FCF? Q1 had repurchases, but net income was $2.9M vs $4.8M prior. Margin is thin. Let's give 2 pts for high yield, but it's borderline.)\nScore: 4 (conservative, maybe 5 for FCF yield, but narrative cautions against cheapness)\n\nE. QUALITY (max 15)\n- roic_pct: null (narrative says ROIC <1%)\n- gross_margin_trend_pp_yoy: 79.3 (gross margin is 79.3%, not trend. Trend is not given as expanding ≥3pp. Actually, gross margin is just a level. Let's assume 0 for trend.)\n- net_debt_to_ebitda: 2.4 (not ≤2x)\nScore: 0\n\nF. MOMENTUM/TECHNICAL (max 10)\n- above_50dma: false\n- above_200dma: true\n- rsi_14: 47 (in 40-65 zone -> 2 pts)\n- macd_recent_bullish_cross: false\n- 12_1_momentum: null\nScore: 2\n\nTotal Score: 0 + 0 + 0 + 4 + 0 + 2 = 6.\nWait, let's double check scoring rules.\nD. MISPRICING: 5 pts for F/E ≥20% below median? The rule says \"5 pts: forward P/E ≥ 20% below sector median (with non-deteriorating earnings)\". Earnings are deteriorating (net income dropped, EPS miss in Q4). So 0 pts here.\n4 pts: FCF yield ≥7% with stable FCF. FCF yield is 10.89%, but is FCF stable? Q1 net income dropped. I'll give 2 pts cautiously, or 0. Let's stick with 2.\nTotal ~6-8.\n\nAnti-signals: \"litigation\", \"concentration\". The prompt says: \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\"\nConcentration > 30% is explicitly an anti-signal gate. Dossier says: \"Customer concentration > 30%\" is an anti-signal. Dossier says: \"Three-wholesaler concentration at 79%\". This triggers the concentration anti-signal gate. I must skip.\n\nAlso, the dossier explicitly says: \"verdict: range_bound_or_income\". Options flow is weak. Catalyst is weak. Quality is weak. Smart money is 0.\nScore is very low. I will skip.\n\nLet's calculate score carefully:\nA: 0\nB: 0\nC: 0\nD: 2 (FCF yield 10.89%)\nE: 0\nF: 2 (RSI 47)\nTotal: 4.\n\nAnti-signal: concentration > 30%. Dossier confirms 79% to 3 wholesalers.\nI will output skip.\n\nStructure the output exactly as requested.\n{\n  \"skip\": true,\n  \"score\": 4,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 0,\n    \"catalyst\": 0,\n    \"mispricing\": 2,\n    \"quality\": 0,\n    \"technical\": 2\n  },\n  \"reason\": \"Fails the concentration anti-signal gate (79% of sales through three wholesalers exceeds the 30% threshold) and scores poorly across all rubric categories due to zero smart-money conviction, deteriorating earnings surprise history, thin margins, and lack of a near-term asymmetric catalyst.\"\n}\n\nCheck constraints:\n- \"ONLY ONE STRUCTURE TYPE.\" -> skip template used.\n- \"OUTPUT ONLY VALID JSON.\" -> yes.\n- Dates: none used in skip.\n- Score breakdown matches rubric caps.\n- Reason is 1-2 sentences.\n\nAll good. Proceed. \nWait, let's verify the concentration anti-signal rule: \"Customer concentration > 30%\" is listed under ANTI-SIGNAL GATES. The dossier says `anti_signals_present: [\"litigation\", \"concentration\"]`. The prompt says: \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\" Since it's 79% wholesaler concentration, it definitely applies. I will skip.\n\nOne minor point: the prompt says \"Customer concentration > 30%\" is a gate. Wholesaler concentration isn't exactly customer concentration, but it's listed as an anti-signal in the dossier. I'll just cite the dossier's anti-signal flag and the low score.\n\nScore calculation check:\nA: 0\nB: 0\nC: 0\nD: 2 (FCF yield 10.89% ≥ 7%)\nE: 0\nF: 2 (RSI 47)\nTotal: 4.\nMatches.\nOutput matches exactly.\nProceed. \nLet's draft carefully. \nAll constraints met.\nOutput matches requested format.\nDone. \nSelf-Correction/Refinement during thought: \nShould I give D any more points? Forward P/E is 6.31 vs 14.5 median. That's >20% below. But condition is \"with non-deteriorating earnings\". Earnings deteriorated (Q4 miss, Q1 net income down). So 0.\nFCF yield 10.89% -> 4 pts? Rule says \"4 pts: FCF yield ≥ 7% with stable FCF\". Q1 net income dropped, but FCF might be stable due to buybacks? I'll stick with 2 to be conservative, or 4. It doesn't change the skip decision. I'll give 2.\nTotal 4.\nSkip is robust.\nOutput matches. \nProceeds. \nJSON generation. \n[Done] \nOutput matches response. \n(Note: I will ensure the JSON is strictly valid and contains no markdown fences as requested: \"OUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.\")\nAll good. \nProceeds. \n```json\n{\n  \"skip\": true,\n  \"score\": 4,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 0,\n    \"catalyst\": 0,\n    \"mispricing\": 2,\n    \"quality\": 0,\n    \"technical\": 2\n  },\n  \"reason\": \"Fails the concentration anti-signal gate (79% of sales routed through three wholesalers) and scores poorly across all rubric categories due to zero smart-money conviction, deteriorating earnings surprise history, thin margins, and lack of a near-term asymmetric catalyst.\"\n}\n```\nWait, the prompt says \"OUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.\" I will output raw JSON.\nCheck score breakdown caps: smart_money max 25, options_flow max 10, catalyst max 25, mispricing max 15, quality max 15, technical max 10. My numbers are within caps.\nAll good.\nProceeds. \nOutput matches exactly. \n[Final Check of the Prompt]\n\"OUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.\"\nI will provide exactly that.\nDone. \n(Self-Correction/Verification during drafting)\nLet's double check the `anti_signals_present` field in the dossier: `[\"litigation\", \"concentration\"]`. The prompt says: \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\" Since it's present, I must skip.\nScore is 4.\nReason is concise.\nReady. \nOutput matches. \nProceeds. \n[Output Generation] -> *Proceeds*\n</think>\n\n{\n  \"skip\": true,\n  \"score\": 4,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 0,\n    \"catalyst\": 0,\n    \"mispricing\": 2,\n    \"quality\": 0,\n    \"technical\": 2\n  },\n  \"reason\": \"Fails the concentration anti-signal gate (79% of sales routed through three wholesalers) and scores poorly across all rubric categories due to zero smart-money conviction, deteriorating earnings surprise history, thin margins, and lack of a near-term asymmetric catalyst.\"\n}",
      "cleaned_content": "{\n  \"skip\": true,\n  \"score\": 4,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 0,\n    \"catalyst\": 0,\n    \"mispricing\": 2,\n    \"quality\": 0,\n    \"technical\": 2\n  },\n  \"reason\": \"Fails the concentration anti-signal gate (79% of sales routed through three wholesalers) and scores poorly across all rubric categories due to zero smart-money conviction, deteriorating earnings surprise history, thin margins, and lack of a near-term asymmetric catalyst.\"\n}",
      "tool_calls": null,
      "finish_reason": "stop"
    }
  ],
  "tool_results": [],
  "final_message": "{\n  \"skip\": true,\n  \"score\": 4,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 0,\n    \"catalyst\": 0,\n    \"mispricing\": 2,\n    \"quality\": 0,\n    \"technical\": 2\n  },\n  \"reason\": \"Fails the concentration anti-signal gate (79% of sales routed through three wholesalers) and scores poorly across all rubric categories due to zero smart-money conviction, deteriorating earnings surprise history, thin margins, and lack of a near-term asymmetric catalyst.\"\n}",
  "tool_calls_total": 0,
  "walltime_ms": 36613,
  "stop_reason": "stop",
  "completed_at": "2026-06-13T01:39:04.344Z"
}